Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden Show more

Location: Luntmakargatan 46, Stockholm, 111 37, Sweden | Website: https://www.oncopeptides.com/sv | Industry: Biotechnology | Sector: Healthcare


Market Cap

55.98M

52 Wk Range

$0.27 - $0.27

Previous Close

$0.26

Open

$0.26

Volume

N/A

Day Range

$0.26 - $0.26

Enterprise Value

20.2M

Cash

178.5M

Avg Qtr Burn

-65.14M

Insider Ownership

34.49%

Institutional Own.

60.99%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.